

Published in final edited form as:

Nat Rev Cancer. 2013 November ; 13(11): 800–812. doi:10.1038/nrc3610.

The microbiome and cancer

Robert F. Schwabe and

Department of Medicine, and Institute of Human Nutrition, Columbia University, College of Physicians and Surgeons, New York 10032, USA

Christian Jobin

Department of Medicine and Department of Infectious Diseases & Pathology, University of Florida, Gainesville, Florida 32611, USA

Robert F. Schwabe: rfs2102@columbia.edu; Christian Jobin: Christian.Jobin@medicine.ufl.edu

Abstract

Microbiota and host form a complex ‘super-organism’ in which symbiotic relationships confer benefits to the host in many key aspects of life. However, defects in the regulatory circuits of the host that control bacterial sensing and homeostasis, or alterations of the microbiome, through environmental changes (infection, diet or lifestyle), may disturb this symbiotic relationship and promote disease. Increasing evidence indicates a key role for the bacterial microbiota in carcinogenesis. In this Opinion article, we discuss links between the bacterial microbiota and cancer, with a particular focus on immune responses, dysbiosis, genotoxicity, metabolism and strategies to target the microbiome for cancer prevention.

Since the late nineteenth century, when Koch postulated that a pathogen must be isolated from the diseased subject, grown in pure culture and cause disease when reintroduced into a susceptible recipient¹, research on microbial interactions with humans has focused on single pathogenic organisms. On the basis of these principles, we have witnessed tremendous progress in our understanding and in the treatment of infectious diseases over the past 100 years. Moreover, we have learned that chronic infections contribute to carcinogenesis with approximately 18% of the global cancer burden being directly attributable to infectious agents^{2,3}. Many pathogens, particularly viruses, promote cancer through well-described genetic mechanisms⁴. Other pathogens, such as *Helicobacter pylori* and hepatitis C virus, promote the development of cancer through epithelial injury and inflammation, which — as postulated by Virchow⁵ 150 years ago — contributes to carcinogenesis^{2,3,6}. However, recent evidence suggests that human disease is attributable not only to single pathogens but also to global changes in our microbiome^{7,8}. Our microbiome — often termed the “forgotten organ” (REF. 9) — contains a metagenome that exceeds our own genome by 100-fold (REFS 10,11) and exerts key functions that are relevant to human health¹². Traditional culture-based methods capture only a small proportion, typically less than 30%, of our bacterial microbiota¹³. Culture-independent analysis using next-generation sequencing has closed this

gap and has been essential in defining and understanding the bacterial microbiome and metagenome, and its key role in metabolism and inflammation^{12,14} — two factors that contribute to carcinogenesis in modern societies^{15,16}. In this Opinion article, we discuss the possible roles of the bacterial microbiome in carcinogenesis, focusing on host–microbiota interactions and effector mechanisms. The contribution of viruses to carcinogenesis has been reviewed elsewhere⁴.

Cancer-modulating effects of microbiota

Microbiota and host have co-evolved into a complex ‘super-organism’, the intricate relationships of which benefit the host in many ways, such as through nutrition and metabolism^{12,14}. However, this close relationship also carries risks for disease development, particularly when host regulatory pathways that guard homeostasis are perturbed. Of the microbial mass, 99% is within the gastrointestinal tract, and it exerts both local and long-distance effects. For this reason, the gastrointestinal microbiome not only has the greatest effect on overall health and metabolic status of all the microbiomes but it is also the best-investigated microbiome and serves as a model for understanding host–microbiota interactions and disease. Other organs with a well-characterized microbiome include the skin and the vagina^{14,17}. The microbiome of each organ is distinct¹⁴, which suggests that effects on inflammation and carcinogenesis are likely to be organ specific. Moreover, there is an important and functionally relevant inter-individual variability of microbiomes¹⁴, which renders them a potential determinant of disease (including cancer) development. In addition, the microbial community and abundance vary in different locations within organs^{14,17}. These differences might be an explanation for the occurrence of diseases, including cancer, in particular locations within an organ; for example, the higher rate of cancer in the large intestine — where microbial densities are much higher than in the small intestine⁹. In the gastrointestinal tract, the bacterial community also varies between luminal- and mucosa-associated communities¹⁸. Although many organs, for example, the liver, do not contain a known microbiome, they may be exposed to microorganism-associated molecular patterns (MAMPs) and bacterial metabolites through anatomical links with the gut^{19–22}.

Studies in germ-free animals have revealed evidence for tumour-promoting effects of the microbiota in spontaneous, genetically-induced and carcinogen-induced cancers in various organs, including the skin, colon, liver, breast and lungs^{21,23–33} (TABLE 1). Similarly, depletion of the intestinal bacterial microbiota in mice, using antibiotics, reduces the development of cancer in the liver and the colon^{21,22,34–37}, as does the eradication of specific pathogens in humans and in mice^{38–40} (TABLE 1). Although most of these studies show tumour-promoting effects of the bacterial microbiota, antitumour effects have also been observed. In the late nineteenth century antitumour effects were observed in patients with sarcomas, after bacterial infections or after the injection of heat-killed bacteria (termed Coley’s toxin)^{41,42}. Subsequent studies implicated specific bacterial components, which were later identified as Toll-like receptor (TLR) agonists and NOD-like receptor (NLR) agonists, as being responsible for many of these antitumour effects; this led to the concept that potent activation of innate immunity may convert tumour tolerance into antitumour immune responses^{43–45}. However, apart from life-threatening infections and TLR- and

NLR-based therapeutic interventions⁴⁴, the bacterial microbiota rarely triggers the degree of innate immune activation that is required for antitumour immune responses, and instead it often induces disease-promoting low-grade chronic inflammation. Indeed, there is increasing evidence from patients and animal models that shows relevant cancer-promoting effects of the microbiota in many organs, particularly in those that are exposed to the microbiota or to MAMPs (TABLE 1). However, mechanisms of microbiota-driven carcinogenesis substantially differ between organs (TABLE 2).

Carcinogenesis triggered by specific bacterial pathogens

Gastric cancer is the prime example for bacterially driven carcinogenesis that is caused by infection with a specific bacterial pathogen^{30,46,47}. Infection with *H. pylori*, which is classified as a carcinogen by the International Agency for Research on Cancer (IARC), may lead to the sequential development of gastritis, gastric ulcer, atrophy and finally gastric cancer⁴⁷. With a worldwide prevalence of ~50%, and with gastric cancer occurring in 1–3% of chronically infected individuals, *H. pylori* infection substantially contributes to global cancer mortality⁴⁷. Although identified as a carcinogenic pathogen, *H. pylori*-induced gastric cancer is promoted by the presence of a complex microbiota, as *H. pylori* mono-associated mice developed fewer tumours than their specific pathogen-free counterparts in a hypergastrinaemic transgenic mouse model³⁰. This may be explained by *H. pylori*-induced gastric atrophy and hypochlorhydria, which renders the stomach susceptible to bacterial overgrowth, and subsequently increased bacterial conversion of dietary nitrates into carcinogens³⁰. In contrast to its promotion of gastric carcinogenesis, *H. pylori* infection lowers the risk of oesophageal adenocarcinoma in humans^{46,48}, which emphasizes the organ-specific effects of the bacterial microbiota in carcinogenesis.

Additional examples of carcinogenesis promoted by specific bacterial pathogens are gallbladder cancer (that is associated with chronic *Salmonella enterica* subsp. *enterica* serovar Typhi and *Salmonella enterica* subsp. *enterica* serovar Paratyphi infections^{49,50}), and mucosa-associated lymphoid tissue (MALT) lymphomas, both of which are examples of tumours that are triggered by adaptive immune responses against specific pathogens. Gastric MALT lymphoma is characterized by clonal expansion of B cells and T helper (T_H) cells that are reactive to *H. pylori*-derived antigens, and regression occurs after *H. pylori* eradication⁵¹. Similarly, infections with *Campylobacter jejuni*, *Borrelia burgdorferi* and *Chlamydia psittaci* are associated with certain lymphomas, and these commonly regress after antibiotic treatment^{52–54} (TABLES 1,2).

Cancers promoted by dysbiotic microbiomes

A wealth of studies in patients and mice has linked the microbiota to colorectal carcinogenesis⁵⁵. In contrast to gastric carcinogenesis, tumour-promoting effects of the microbiota in colorectal cancer (CRC) seem to be caused by altered host–microbiota interactions and by dysbiosis, rather than by infections with specific pathogens. Accordingly, germ-free status and treatment with wide-spectrum antibiotics led to a significant reduction of the numbers of tumours in chemical and genetic experimental models of colorectal carcinogenesis^{25,27,32–34,36,37}. The liver does not contain a known microbiome and it provides a prime example of cancer that is promoted by dysbiotic

microbiota through long-distance mechanisms. Intestinal bacteria may promote liver cancer through proinflammatory MAMPs and bacterial metabolites, both of which reach the liver via the portal vein^{21,22,35}. Notably, hepatic exposure to cancer-promoting MAMPs and metabolites is increased in liver disease, and has been linked to intestinal dysbiosis^{19–22}. Accordingly, germ-free status and non-absorbable antibiotics reduce hepatic inflammation, fibrosis and hepatocellular carcinoma (HCC) development in mice^{20–22,35}, whereas treatment with the TLR4 agonist lipopolysaccharide (LPS) increases HCC development²¹. Similar to the liver, the pancreas does not have a known microbiome. Recent studies suggest that inflammatory MAMPs, such as LPS and its receptor TLR4, promote pancreatic cancer⁵⁶. Moreover, there is an association of the oral microbiome and periodontitis with pancreatic cancer^{57,58}. However, the mechanisms by which the bacterial microbiota and MAMPs promote pancreatic cancer remain elusive.

There are considerable gaps in our knowledge about the role of the microbiota in carcinogenesis in many other organs that have a substantial bacterial microbiome, such as the lungs, skin, oral cavity and female genital tract. Several findings indicate a possible role for bacteria in the promotion of lung cancer, such as the increased bacterial colonization in chronic obstructive pulmonary disease (COPD^{59,60}; which is a known risk factor for lung cancer development⁶¹), a lower incidence of lung cancer in germ-free male rats, and the promotion of lung cancer by LPS or by chronic respiratory infections^{24,62}. Similarly, the reduced rate of skin cancer in germ-free rats²³ and in mice lacking receptors or adaptor molecules for pro-inflammatory bacterial MAMPs^{63–65} also suggests a possible role for the bacterial microbiota in skin carcinogenesis.

Host–microbiota interplay in cancer

Mechanisms controlling host–microbiota interactions in the super-organism

Millions of years of evolution have seen the host and its surrounding microbial environment co-evolve into a complex super-organism in which numerous relationships such as commensalism, mutualism and parasitism are established within the ecosystem^{66,67}. Microbial communities, which either benefit or do not harm the host, have an evolutionary advantage at establishing a permanent niche and reside in a state of immune tolerance with their host, whereas those that adopt a pathogenic relationship on entering the ecosystem activate robust innate and adaptive immune responses⁶⁸. A key principle that allows the symbiotic coexistence between host and microbiota is the anatomical separation of microbial entities from the host compartment by well-maintained, multi-level barriers. Perturbation of these barriers promotes inflammation and diseases, including cancer. The barriers rely on an intact epithelial lining, sensing systems that detect and eliminate invading bacteria, and in some cases on additional features such as a mucous layer (in the gut), the stratum corneum (in the skin) and a low pH (in the skin and the stomach). Furthermore, specific cell types, such as Paneth and goblet cells in the gut and keratinocytes in the skin, monitor bacterial number and location, and regulate the microbiota through the secretion of antibacterial peptides^{69,70}. Barriers are also enriched in specific subsets of immune cells, such as gut-associated lymphoid tissue (GALT), Langerhans cells in the skin and T_H17 cells at mucosal surfaces^{70,71}. In the gut, secreted immunoglobulin A represents an additional mechanism by

which the host controls the microbiota; this host mechanism limits the access of intestinal antigens to the circulation and limits the invasiveness of potentially dangerous bacterial species⁷². Besides host mechanisms, the microbiome itself represents a functional luminal barrier⁷³ by maintaining epithelial cell turnover, by mucin production and by competing for resources, thereby suppressing the growth of pathobionts. A prime example for the protective role of the commensal microbiota is infection with *Clostridium difficile*, which only thrives and causes disease when the indigenous gut microbiota is suppressed by antibiotics, and which can be cured by microbiota transplantation from healthy individuals⁷⁴. Similarly, germ-free mice have an increased susceptibility to infection with pathogens⁷⁵. In addition to resource competition with metabolically related strains⁷⁵, commensal bacteria also suppress pathobionts and pathogens using active interference mechanisms such as the production of bacteriocins⁷⁶.

Failure of these control mechanisms — that is, barrier defects, immune defects and the loss of eubiosis — have been associated with microbially driven carcinogenesis. Importantly, regulatory mechanisms are tightly linked, and failure of one control mechanism typically perturbs the overall equilibrium (FIG. 1). As such, infection with *H. pylori* not only directly injures host cells, but also changes the gastric environment and barrier, increasing inflammation and altering the microbiota⁴⁷. Another example of the interdependence between the barrier, immunity and the microbiota is the finding that inactivating mutations, or the absence of key components of inflammasomes — nucleotide-binding oligomerization domain-containing 2 (NOD2) and NOD-, LRR- and pyrin domain-containing 6 (NLRP6) — or of interleukin-10 (IL-10), not only affect host inflammatory responses but may also lead to dysbiosis and to bacterial translocation^{77–79}.

Barrier failure in carcinogenesis

The most relevant pathomechanism for bacterially driven carcinogenesis is barrier failure, which results in increased microbiota–host interactions. Barrier failure can result from primary defects in genes that encode proteins that are essential to maintain a functional barrier, or from secondary defects owing to infection, inflammation and carcinogenesis. The relationship between barrier failure and carcinogenesis is complex: barrier failure may trigger inflammation and carcinogenesis, but inflammation and carcinogenesis may also promote barrier failure, thus suggesting the existence of forward-amplifying loops. Clinically, the best known example of barrier failure is ulcerative colitis, in which defects in the intestinal barrier not only contribute to disease development but also increase the risk of cancer⁸⁰. Accordingly, genome-wide association studies have found mutations in crucial barrier proteins, such as laminins, in patients with ulcerative colitis^{81,82}.

The promotion of cancer by a defective barrier is shown by mucin 2-knockout (*Muc2*^{−/−}) mice, which lack the most abundant gastrointestinal mucin and which spontaneously develop CRC⁸³. In experimental colorectal carcinogenesis, bacterial translocation was detected at sites of tumour initiation, and eradication of the bacterial microbiota by antibiotics reduced CRC development³⁶. Another example of barrier defects contributing to cancer development is HCC. Increased translocation of bacteria and of bacterial MAMPs, which are a hallmark of advanced liver disease¹⁹, promotes HCC development and can be

reduced by germ-free status or by antibiotics^{21,35}. Although genetic defects in the keratin-associated protein filaggrin affect the barrier function in the skin and contribute to atopic dermatitis⁸⁴, they have not been associated with cancer development. Thus, barrier defects may require organ-specific ‘second hits’ to promote cancer development.

Bacterial dysbiosis in carcinogenesis

Longitudinal studies show considerable taxonomic (but little metagenomic) variation of the normal human microbiota^{14,85,86}. Perturbations may occur through changes in diet, innate immune responses and inflammation, or infections, and may affect microbial composition, richness and the metagenome^{77,87,88}. Besides the well-established cancer-promoting role of specific pathogens in certain cancers (TABLE 2), a contribution of specific bacteria to human carcinogenesis generally remains elusive. Additional bacterial pathogens such as *Enterococcus faecalis*, enterotoxigenic *Bacteroides fragilis* and *Helicobacter hepaticus* promote cancer in animal models^{89–94}, but there is no clear epidemiological link to human carcinogenesis.

However, direct manipulation of the microbial community using germfree, gnotobiotic, antibiotic-treated and co-housed mice has revealed the essential role of commensal microbiota in CRC and HCC^{21,22,35,36,78,79,95,96}. Indeed, thought-provoking studies involving *Nod2*^{-/-}, *Asc*^{-/-} (also known as *Pycard*^{-/-}) and *Nlrp6*^{-/-} mice, suggest that dysbiosis is sufficient to promote cancer^{78,79}. Obesity is one of the best-studied conditions that leads to dysbiosis, with increased populations of Firmicutes and decreased populations of Bacteroidetes observed in the gut of both humans and mice^{88,97}, as well as a decrease in microbial richness and the associated ‘dysmetabolism’ in humans^{98,99}. Notably, obesity is a well-established risk factor for cancer development, contributing to ~15–20% of cancer¹⁰⁰. In liver cancer, obesity causes cancer-promoting dysbiosis, with increased prevalence of Clostridia that produce the secondary bile acid deoxycholic acid (DCA), which in turn promotes HCC development²². However, direct evidence of the cancer-promoting effect of specific Clostridia strains — for example, through co-housing experiments or the use of gnotobiotic mice — is still lacking. In the colon, dietary fat increases taurocholic acid production, which leads to the expansion of the pathobiont *Bilophila wadsworthia* and to colitis in *Il10*^{-/-} mice¹⁰¹, but a direct link between obesity-induced dysbiosis and CRC also remains to be established.

Microbial dysbiosis in the luminal or the mucosal compartment of patients with CRC has been reported by numerous investigators^{102–105}, but these findings remain largely correlative. However, from these data sets, *Fusobacterium* spp. — particularly *Fusobacterium nucleatum* — emerge as a potential candidate for CRC susceptibility^{106–109}. *F. nucleatum* is far less common in the gut microbiome of healthy individuals than it is in the gut microbiome of patients with Crohn’s disease¹¹⁰. Notably, clinically isolated *F. nucleatum* promotes intestinal carcinogenesis in adenomatous polyposis coli (*Apc*)^{Min/+} mice¹⁰⁷. The *F. nucleatum* adhesin FadA binds to E-cadherin and activates β -catenin in CRC cells, thereby promoting inflammation and E-cadherin-mediated tumour cell growth¹⁰⁹. Importantly, *fadA* levels are significantly increased in human CRC tissue samples¹⁰⁹.

As the bacterial microbiota has a high redundancy at the metagenomic level¹⁴, it is possible that cancer-promoting effects are conferred by different classes of bacteria but through similar pathways, and that alterations in microbial richness and function (rather than true dysbiosis) affect carcinogenesis. Moreover, horizontal gene transfer occurs between pathogens and commensal bacteria, particularly in the context of pathogen-induced inflammation¹¹¹, which suggests the possibility of cancer-promoting gene transfer between bacteria.

The mechanisms that contribute to dysbiosis and to alterations in microbial richness are not yet understood. Host-derived immune and inflammatory responses are an important driving force that shape the microbial community composition and, when altered, that may contribute to dysbiosis, as seen in *Il10*^{-/-}, *Nod2*^{-/-}, *Asc*^{-/-} and *Nlrp6*^{-/-} mice^{77–79,112}. In addition to microbial regulation by innate immunity, inflammation (with its complex set of mediators) may also contribute to a milieu that favours the outgrowth of specific bacteria. Inflammation alters the production of specific metabolites, such as nitrate that is derived from the activity of inducible nitric oxide synthase (iNOS; also known as NOS2). Nitrate may provide a unique source of energy for facultative anaerobic bacteria (for example, Enterobacteriaceae), allowing them to thrive within a community dominated by obligate anaerobic bacteria that lack the proper electron transport chain to use nitrate¹¹³. Accordingly, a bloom of Enterobacteriaceae has been observed across numerous inflammatory disease models and in patients with chronic inflammation^{114–116}. Finally, inflammation induces expression of stress-response genes in bacteria, which is an effect that could promote bacterial fitness and adaptability¹¹⁷; for example, *Escherichia coli* from *Il10*^{-/-} mice with intestinal inflammation show an increased expression of small heat shock proteins IbpA and IbpB, which protects this bacterium from oxidative stress¹¹⁷. Furthermore, it has been suggested that specific low-abundance microorganisms, termed ‘keystone pathogens’ or ‘alpha-bugs’, may further amplify dysbiosis in disease states by exerting dominant effects on the bacterial composition¹¹⁸.

Mechanisms of carcinogenesis

The microbiota is sensed by multiple pattern recognition receptors (PRRs), which monitor microbial status and barrier integrity, and which initiate regulatory responses. These PRRs may not only control the microbiota through antibacterial mediators and thereby suppress cancer, but may also promote resistance to cell death — one of the hallmarks of cancers¹¹⁹ — and may trigger cancer-promoting inflammation. In addition, the microbiota affects carcinogenesis through the release of carcinogenic molecules, such as genotoxins, and through the production of tumour-promoting metabolites.

Microbiota-induced activation of TLRs in carcinogenesis

Microbial pattern recognition by TLRs is a cornerstone of innate immunity and it represents one of the most powerful pro-inflammatory stimuli¹²⁰. Accumulating evidence indicates that bacterial MAMPs and TLRs are contributors to carcinogenesis. TLR4, the receptor for the Gram-negative bacterial cell wall component LPS, promotes carcinogenesis in the colon, liver, pancreas and skin, as shown by reduced tumour development in *Tlr4*-deficient mice^{21,56,64,121} and by increased tumour load in mice expressing constitutively activated

epithelial-derived TLR4 (REF. 122). TLR2, which is the receptor for the bacterial cell wall components peptidoglycan and lipoteichoic acid, promotes gastric cancer¹²³. TLRs promote epithelial carcinogenesis through epithelial cells, stromal fibroblasts and through bone marrow-derived cells. A key cancer-promoting downstream effect of TLR signals is the induction of survival pathways, which is mediated by activation of nuclear factor- κ B (NF- κ B) and signal transducer and activator of transcription 3 (STAT3)^{21,121,123}. Although there is strong evidence that tumour cells express TLRs^{121,123}, conditional ablation strategies are required to determine whether activation of TLR signalling directly affects the survival of tumour cells, or whether tumour cell survival is indirectly affected through TLRs that are expressed in the tumour stroma. The pro-survival function of the TLR–myeloid differentiation primary response 88 (MYD88) pathway is highlighted by the finding that human lymphomas often contain an activating point mutation in *MYD88* that triggers NF- κ B and STAT3 activation¹²⁴. In the intestine, microbiota-induced activation of TLRs on myeloid cells triggers an IL-17 and IL-23 pro-carcinogenic pathway, as shown by their decreased expression after antibiotic treatment or genetic inactivation of *Myd88*, *Tlr2*, *Tlr4* or *Tlr9* (REF. 36). Importantly, carcinogenesis is reduced by genetic or pharmacological inhibition of IL-17 and IL-23 signalling^{36,92}. TLRs may also promote tumour proliferation, which is thought to be mediated through mitogens such as epiregulin, amphiregulin and hepatocyte growth factor (HGF) that are released from TLR-expressing stromal fibroblasts; this has been shown in the colon and in the liver^{21,121,125,126}.

It should be emphasized that signalling pathways used by TLRs, such as MYD88, often have multiple functions, and that complete ablation not only affects malignant cells but also affects the function of normal epithelia. In the intestinal epithelium, MYD88 functions as a gatekeeper of epithelial integrity. This may explain why MYD88 deficiency not only suppresses the development of cancer^{127–130} but also promotes carcinogenesis in models with substantial epithelial damage, such as in the model of dextran sodium sulphate (DSS)-promoted CRC^{56,131}. The increased damage possibly masks potential tumour-suppressive effects of reduced MYD88-mediated inflammation in these models. MYD88 is also a mediator of IL-18 signalling, and the absence of MYD88 may therefore promote carcinogenesis by blocking the activity of an IL-18-dependent pathway that influences microbial composition (discussed below).

Microbiota-induced activation of NLRs in carcinogenesis

NLRs are a family of PRRs that are characterized by a central NOD domain¹¹². NOD2, a muramyl dipeptide-sensing NLR, has been the focus of many studies because its loss of activity is associated with Crohn's disease⁸⁰. Notably, inactivating polymorphisms in *NOD2* have been associated with increased susceptibility to CRC in several cohorts¹³². Similar to what is seen in patients with Crohn's disease, *Nod2* deficiency leads to increased CRC in mice⁷⁸. NOD2 exerts a key role in bacterial immunity, as shown by the increased susceptibility of NOD2-deficient mice to bacterial infections, and by the decreased ability of NOD2-deficient crypts to kill commensal bacteria^{133,134}. Interestingly, *Nod2*^{-/-} mice, as well as patients with *NOD2* mutations, also have intestinal dysbiosis¹³⁵. Indeed, a thought-provoking study has recently suggested that the increased cancer susceptibility in NOD2-

deficient mice is a consequence of dysbiosis, as the increased cancer development was transferable to wild-type mice by co-housing⁷⁸.

A second NLR implicated in the host–microbiota interaction and in bacterially driven carcinogenesis is NLRP6. NLRP6 is a component of inflammasomes and it contributes to their activation, as shown by decreased levels of IL-18 in *Nlrp6*^{−/−} mice⁷⁹. Similar to *Nod2*^{−/−} mice, *Nlrp6*^{−/−} mice have dysbiosis that makes them more susceptible to colitis and CRC development. The dysbiosis-driven carcinogenesis in *Nlrp6*^{−/−} mice is a result of decreased inflammasome activation and IL-18 production, as shown by the increased susceptibility of *Asc*^{−/−} and *Il18*^{−/−} mice to CRC, and by the ability of these mice to transmit this disease to wild-type mice in co-housing studies⁷⁹. IL-6 represents a common mediator of the tumour-promoting effects of dysbiotic *Nod2*^{−/−} and *Nlrp6*^{−/−} mice, as shown by reduced CRC development in mice that are treated with neutralizing IL-6 receptor (IL-6R) antibodies and in mice with *Il6r* ablation^{78,79}. NOD1 also has a role in intestinal defence against bacteria, and NOD1 variants have been implicated in inflammatory bowel disease in humans¹³⁶. Notably, NOD1 deficiency negatively affects the intestinal barrier and it promotes inflammation- and genetically-induced CRC, which can be suppressed by depletion of the gut microbiota by antibiotic treatment³⁴. Other NLRs such as NLRP3, NLRP12 and NOD-, LRR- and CARD-containing 4 (NLRC4) also have a role in colitis-associated cancer^{137–139}, but the functional contribution of these innate sensors to microbially driven carcinogenesis remains unclear.

Bacterial-derived genotoxins

Although the ability of some bacteria to induce chronic inflammation (and an associated increase in reactive oxygen species (ROS)-mediated genotoxicity) clearly contributes to their carcinogenic potential, microorganisms also have the capacity to directly modulate tumorigenesis through specific toxins that induce DNA damage responses (FIG. 2). As discussed above, alterations in barrier function may allow luminal bacteria (such as adherent-invasive *E. coli*) access to the epithelium, where direct contact with host cells enables the bacteria to transfer or to deliver specific toxins. Bacterial toxins, such as cytolethal distending toxin (CDT), cytotoxic necrotizing factor 1, *B. fragilis* toxin and colibactin, affect crucial cellular responses that are implicated in tumorigenesis, particularly responses to DNA damage^{77,92,140–142}. However, only CDT and colibactin exert direct DNA damage responses and genomic instability, and are therefore considered genotoxic^{141,142}. Both of these genotoxins trigger double-strand DNA damage responses, including activation of the ataxia-telangiectasia mutated (ATM)–CHK2 signalling pathway and phosphorylation of histone H2AX, which lead to transient G2/M cell cycle arrest and to cell swelling.

CDT is produced by Gram-negative bacteria and is by far the most wellcharacterized genotoxin. Microorganisms relevant to colorectal, gastric and gallbladder cancer (such as *E. coli*, *Helicobacter* spp. and *S. Typhi*) are all CDT producers¹⁴³. Upon infection, the CdtA and CdtC subunits form an anchor between the bacterium and the host cell to allow delivery of the active subunit CdtB into the cytoplasm, from where it travels to the nucleus and confers DNase activity-mediated DNA damage¹⁴¹. Mutation of residues in the active site of

CdtB, which are highly homologous to those in mammalian DNase I sites, reduces DNA damage responses *in vitro*, including cell cycle arrest^{141,144}. CDT-mediated DNase activity may also be important for the carcinogenic potential of CDT-carrying bacteria, such as *C. jejuni* and *Helicobacter cinaedi*, because CdtB-mutant strains failed to elicit intestinal hyperplasia in mice lacking NF- κ B subunits, *p50* (also known as *Nfkb1*) and one allele of *p65* (also known as *Rela*), and failed to elicit dysplasia in *Il10*^{-/-} mice^{145,146}.

Colibactin, which is encoded in the 54 kb polyketide synthase (*pks*) genotoxicity island, is another important genotoxin that has attracted recent attention. *pks*-containing bacteria mostly belong to the Enterobacteriaceae family, with *E. coli* from the B2 groups representing the predominant carrier¹⁴⁷. Recently, the murine isolate *E. coli* NC101 *pks* was functionally linked to CRC development in gnotobiotic *Il10*^{-/-} mice⁷⁷, and the *pks* island was more prevalent in mucosa-associated *E. coli* clinical isolates obtained from patients with CRC compared with those obtained from controls^{77,148}. Interestingly, *Proteus mirabilis* and *Klebsiella pneumoniae*, two microorganisms that can induce a maternally transmissible colitis in immunodeficient mice that are deficient in both T-bet (also known as TBX21) and recombination activating gene 2 (RAG2; *Tbet*^{-/-}*Rag2*^{-/-} mice)¹⁴⁹, are also *pks* carriers¹⁵⁰. Whether *P. mirabilis*, *K. pneumoniae* and colibactin are functionally implicated in the development of CRC observed in *Tbet*^{-/-}*Rag2*^{-/-} mice⁹⁵ remains to be determined. Colibactin has not been isolated and purified, but it is known that eight of nine accessory genes, and all the PkS and nonribosomal peptide synthetase (NRPS) subunits, are required to generate active colibactin with DNA-damaging capacity¹⁴⁷. At the molecular level, *E. coli* *pks*-positive strains induce double-strand DNA breaks and associated DNA damage responses (mediated by ATM), cell cycle arrest and genomic instability^{77,142}. Colibactin genotoxicity and carcinogenic effects might be mediated by DNase activity. This hypothesis is supported by the finding that DNA integrity in cells infected with *E. coli* *pks*⁺ strains is compromised compared with *pks*-defective isogenic mutants¹⁴⁷. Whether this effect is the direct result of colibactin, as is the case for CDT, or is due to an intermediate target, needs further investigation.

Moreover, various bacterial-derived metabolites such as hydrogen sulphide and superoxide radicals may cause genomic instability^{151,152}. For example, *Enterococcus faecalis* can generate large amounts of extracellular superoxide, which causes double-strand DNA breaks and chromosome instability^{152,153}; this leads to the development of CRC in *Il10*^{-/-} mice^{154,155}. *E. faecalis* mutants that are defective in extracellular superoxide production (for example, Δ *menB* strain) fail to promote tumorigenesis in *Il10*^{-/-} mice compared with mice colonized with the parental *E. faecalis* strain^{154,155}. Sulphate-reducing bacteria — which mostly belong to the class of Fusobacteria (which has recently been linked to CRC^{106,156} and tumour development in preclinical models¹⁰⁷) and to the class Deltaproteobacteria — promote the generation of hydrogen sulphide, which is a gas with genotoxic properties¹⁵⁷. Host-mediated detoxification and/or microbial-mediated elimination (or use) of these genotoxic products are likely to have an effect on host cellular homeostasis and on carcinogenesis.

Bacterial virulence factors

Disease-promoting and cancer-promoting effects of pathogens often depend on virulence factors. This is exemplified by increased inflammation and cancer rates in *H. pylori* strains expressing the virulence factors cytotoxin-associated gene A (CagA) or vacuolating cytotoxin A (VacA)⁴⁷. Virulence factors may use specific host-derived signalling pathways that result in the activation of tumour-promoting pathways, as demonstrated by the activation of the tyrosine phosphatase SHP2 (also known as PTPN11) and by the development of gastric cancers in transgenic mice expressing CagA, but not phosphorylation-resistant CagA¹⁵⁸. In addition, *F. nucleatum* uses the virulence factor FadA to adhere to and invade cells¹⁵⁹, and was recently shown to interact with E-cadherin to activate β -catenin signalling and to promote CRC development¹⁰⁹. Virulence factors found in other pathogens and commensal bacteria are likely to contribute to carcinogenesis, but this requires further investigation.

Microbial-derived metabolism affecting carcinogenesis

Human metabolism represents a combination of microbial and human enzyme activities¹¹. The bacterial metagenome is functionally far more diverse than that of humans, and is enriched for genes that are relevant for nutrient, bile acid and xenobiotic metabolism, as well as for the biosynthesis of vitamins and isoprenoids^{11,160}. These metabolic activities, generated by the oral and intestinal microbiota, may affect carcinogenesis by regulating obesity and obesity-induced inflammation, metabolic activation and inactivation of carcinogens (which includes the generation of nitrosamines and the conversion of alcohol to acetaldehyde), metabolic activation or inactivation of dietary phytochemicals, metabolism of hormones and the generation of tumour-promoting secondary bile acids.

Gut bacteria regulate bile acid metabolism through various hydrolase activities, which remove polar groups — for example, taurine — from conjugated bile acids, thereby affecting bile acid composition and enterohepatic circulation, and allowing microorganisms to use secondary bile acids as an energy source¹⁶⁰. Recent studies suggest that a high-fat diet alters the gut microbiome and increases the levels of the secondary bile acid DCA, which is a metabolite that is solely produced by bacterial 7 α -dehydroxylation. Notably, in this high-fat diet model, DCA supplementation increases HCC development, whereas reduction of DCA-producing bacteria by antibiotics decreases it²². DCA is also known to promote colon and oesophageal cancer, which suggests that the microbiome may also affect these cancers through DCA production, particularly in the context of obesity^{22,161,162}.

Microbial carbohydrate fermentation may benefit the host through the generation of short-chain fatty acids¹⁶³, whereas protein fermentation may have negative consequences owing to the generation of potentially toxic and cancer-promoting metabolites, such as ammonia, amines, phenols, sulphides and nitrosamines^{151,164–166}. As protein fermentation mainly occurs in the distal colon, this might contribute to the higher rate of cancers in the distal (small) versus the proximal (large) intestine. High-protein, low-carbohydrate diets may change intestinal fermentation, leading to increased levels of hazardous metabolites, such as nitrosamines, and to decreased levels of cancer-protective metabolites, such as butyrate and plant-derived phenolic compounds¹⁶⁷. In particular, short-chain fatty acids including butyrate

have a known role in the regulation of inflammation and autophagy, and have been implicated in protection from colon and liver cancer^{168–171}. Health-promoting, antioxidant and cancer-preventing properties of plant-derived products are often attributed to phytochemicals, including polyphenols such as theaflavins, thearubigins, epigallocatechin-3-gallate and flavonoids^{172–174}. Through its large enzymatic capacity, the microbiota synthesizes, bioconverts or degrades isoprenoids and polyphenols (including flavonoids), thus controlling their local and systemic effects on health and cancer development^{11,173,175–178}. The gut microbiota also modulates the biological activity of lignans^{177,179}, a class of phytoestrogens that reduces cancer incidence¹⁸⁰, thereby affecting cancer development. Although the microbiota is necessary for phytochemical-mediated anticancer properties, the microbial entities and complex partnerships that contribute to these beneficial effects remain unclear.

The intestinal microbiota also has a major role in the metabolism of xenobiotics¹⁸¹. As such, it influences the activity and the side effects of drugs used for antitumour therapies. For example, *irinotecan* is inactivated by the liver but reactivated by bacterial β -glucuronidase, which leads to severe treatment-limiting side effects such as diarrhoea¹⁸²; notably, treatment with antibiotics or inhibitors of bacterial β -glucuronidase prevents these complications¹⁸².

The microbiota also contributes to the activation^{28,183,184} and the inactivation of carcinogens^{185,186}, thereby modulating carcinogenesis. Importantly, the bacterial microbiota contributes to the metabolism of alcohol, which is responsible for ~3.6% of all cancers¹⁸⁷, including cancers of the oral cavity, pharynx, oesophagus, colon, rectum, female breast and liver. Germ-free rats have significantly lower concentrations of acetaldehyde¹⁸⁸, which mediates many of the disease-promoting and genotoxic effects of alcohol¹⁸⁷. The contribution of bacterial acetaldehyde generation may be particularly important in cancers of the oral cavity, where further metabolism of acetaldehyde is limited, leading to 10–100-fold higher acetaldehyde concentrations than in the blood¹⁸⁷.

The bacterial microbiota may also have a role in the metabolism of hormones, including oestrogens¹⁸⁹ and testosterone¹⁹⁰. In particular, the microbiota modulates the enterohepatic circulation of oestrogens through their ability to deconjugate oestrogens, thus affecting circulating and excreted oestrogen levels¹⁸⁹, and the risk for development of oestrogen-dependent cancers¹⁸⁹.

In summary, the intricate relationship between the microbiota and the host in respect to tumour-promoting and tumour-suppressive components of our diets and lifestyles is only starting to be appreciated. Consumption of unhealthy diets, obesity, alcohol and smoking are all known to modulate microbiomes and to contribute to carcinogenesis. The relative contribution of microbiomes and microbial metabolism to the carcinogenesis that is promoted by these unhealthy lifestyles remains to be determined.

Open questions and crucial issues

Although the link between the microbiota and cancer has been recognized, several key questions remain unanswered in this rapidly evolving field of research.

Evidence for a contribution of microbiomes in human carcinogenesis

The functional relevance of human microbiomes to cancer development has not been established. Transferring human cancer microbiomes to preclinical models would help to assess the tumorigenic potential of the cancer-associated microbiota. However, experiments using cross-species transplantation need to take into account host-specific microbiota effects on the immune system¹⁹¹, which are an important component of the carcinogenic process.

Multifaceted and large-scale approaches that integrate metagenomic, metatranscriptomic and metabolomic analysis from large cohorts of patients and healthy controls will be essential in establishing the role that microbiomes have in cancer development, in an organ- and cancer-specific manner, and will allow investigators to determine whether changes in microbial composition or richness, in particular at the metagenomic level, affect cancer development. Validation of the cancer-inducing potential of clinical bacterial isolates would require the use of various animal models, combined with different housing conditions — specific pathogen-free (SPF) and germ-free conditions, as well as gnotobiotics — to clearly establish cause–effect relationships. Furthermore, testing clinical isolates in more than one model is also important as, for example, *F. nucleatum* promotes colorectal cancer in *Apc*^{Min/+} mice but not in *Il10*^{-/-} mice¹⁰⁷.

The contribution of extra-intestinal microbiomes to carcinogenesis

Most current data on the microbiota and cancer focus on the gut microbiome. Although the gut microbiome dominates in number, other microbiomes may also have relevance to cancer; for example, the contribution of the lung microbiome to lung cancer is clearly understudied, and understanding this possible link may be relevant. Similarly, further insight into the roles of microbiomes of the skin and the urogenital tract could be highly relevant.

Identification of bacteria and bacterial mediators or metabolites that promote cancer

Identification of key contributors to microbiota-driven carcinogenesis is required to develop therapeutic approaches. Innovative techniques, including novel cultivation media, particularly for anaerobic conditions¹⁹², and novel culture techniques such as microfluidic continuous cultures¹⁹³ will be necessary to overcome the limited range of bacteria that can currently be cultured and that can subsequently be characterized *in vitro* or in gnotobiotic animal models. Although gnotobiotic models are a powerful tool to understand microbial contributions to carcinogenesis, this experimental approach does not reflect the complex composition of the microbiome that is found in humans; indeed, it may either overemphasize effects owing to artificial abundance of a single species or of a group of bacteria, or it may not reveal effects that are due to the requirement of a complex microbial community for the induction of disease by some bacteria¹⁴⁹. It will be important to identify the environmental conditions that lead to under-representation and overrepresentation of bacterial species that are associated with cancer, and to mimic these conditions in experimental models.

In addition to identifying the specific bacteria that contribute to carcinogenesis, the identification of the mediators through which these bacteria promote cancer is essential to advance therapeutic interventions. The recent discovery of the roles of bacterial genotoxins

and secondary bile acid metabolites as key effectors in mouse carcinogenesis is a first step towards understanding how bacteria may directly promote cancer. Large-scale and deep-sequencing analyses, in combination with proteomics and metabolomics, are likely to uncover additional genotoxic islands and cancer-promoting metabolites or other factors present in clinical isolates.

The interplay between inflammation and the microbiome in carcinogenesis

Although inflammation is an important environmental trigger that shapes microbial composition^{194,195}, it is not clear whether dysbiosis is fostered by the progression of inflammatory grades or whether other factors (such as host genetics or diet) imprint early microbial dysbiosis, which then promotes inflammation. This cause–effect relationship will need to be investigated in more detail using longitudinal microbiome analysis in conjunction with the measurement of inflammatory markers. Similarly, the functional effect of innate sensors such as TLR2, TLR4 and TLR5 on microbial composition has been questioned¹⁹⁶; for example, although the dysbiotic microbiota from *Nod2*^{−/−} mice transfers carcinogenesis to wild-type mice⁷⁸, several groups have found no evidence of dysbiosis in *Nod2*^{−/−} mice^{197,198}. These findings do not negate the observation that the microbiota could transfer a given disease phenotype, but they certainly do question the causative link between a specific genotype (for example, *Nod2*^{−/−}) and dysbiosis. This highlights the need to carry out additional experiments in which familial transmission¹⁹⁶ and stochastic changes¹⁹⁹ are carefully monitored and assessed before firm conclusions are reached about dysbiosis and the host genotype. Moreover, many PRRs not only regulate innate immunity and inflammation but also regulate barrier integrity. An alternative mechanistic explanation for the effects of PRRs in carcinogenesis could be that a breach of barriers owing to insufficient PRR activity constitutes the key trigger in microbially driven inflammation and carcinogenesis. In this scenario, dysbiosis could be an epiphenomenon to the pathology.

Another important unanswered question is the relationship between the microbiome and cancer therapeutic responses. Although the influence of the gut microbiota in shaping local and systemic immune responses has been recognized¹⁹⁵, the effect of this biological function on the efficacy of antitumour agents is unknown.

Possible future therapeutic applications

The many mechanisms by which the microbiota modulates carcinogenesis, including inflammation, metabolism and genotoxicity (FIG. 2), provide possibilities to target the microbiome for cancer prevention strategies. Although additional data linking the contribution of the microbiome to specific cancers, particularly in humans, need to be generated, microbiota-based strategies for cancer prevention can be envisioned (FIG. 3). Prebiotics, probiotics or microbiota transplants may restore eubiosis in chronic disease states, thereby reducing microbially-induced genotoxicity and activation of inflammatory, proliferative and antiapoptotic pathways. Limited-spectrum and non-absorbable antibiotics may be used to target genotoxic, DCA-producing or translocating bacteria; for example, in patients at a high risk of developing CRC or HCC. Genetically altered microbiota expressing or lacking specific enzymes²⁰⁰ — in combination with matched diets — might be used to achieve higher levels of tumour-suppressive phytochemicals or lower levels of tumour-

promoting substances, or to suppress tumour-promoting bacterial species. Pharmacological targeting of inflammatory pathways that are activated by the bacterial microbiota may reduce cancer-promoting inflammation, and pharmacological approaches may be used to target bacterial genotoxins and enzymes that promote cancer.

Understanding the diverse contributions of the bacterial microbiota to carcinogenesis will open new possibilities for diagnostic, preventative and therapeutic approaches. Although it is likely that many of the underlying mechanisms are disease- or organspecific, mining the microbiome holds much promise and clearly represents the next frontier of medical research.

Acknowledgments

R.F.S. was supported by grants from the US National Institutes of Health (NIH) U54CA163111, R01DK076920 and R01AA020211. C.J. acknowledges support from the NIH (R01DK047700 and R01DK073338). The authors thank D. Dapito for critical reading of the manuscript.

Glossary

Adaptive immune responses	As opposed to innate immunity, adaptive immune responses are specific to the type of pathogen that is encountered, thereby providing a tailored (albeit slower) immune response. This acquired response is typically mediated by B and T cells with the subsequent generation of memory cells
Bacteriocins	Antimicrobial peptides released by bacteria to inhibit growth of similar or closely related microorganisms
Commensalism	A relationship between two organisms in which one organism benefits, whereas the other does not
Dysbiosis	A state of microbial composition that is characterized by an unbalanced proportion of bacteria compared with the proportion in a healthy state
Eubiosis	A state of microbial composition in which population abundances are found in normal proportions and typically associated with healthy individuals
Facultative anaerobic bacteria	Bacteria that are able to generate energy (ATP) through aerobic respiration (electron transport chain) or through fermentation, depending on the amount of oxygen or fermentable products available
Germ-free animals	Animals born and raised in a sterile environment; they lack any microorganisms (except endogenous viruses)
Gnotobiotic	Describes an animal with a defined microbial population. These animals are born germ-free and then known microorganisms are introduced; this requires that the animals are housed in isolation, to maintain their defined microbial status

Horizontal gene transfer	The movement of genetic material from one organism to another, without the need for cell division
Innate immunity	An immune response that recognizes conserved microbial structures, typically through the action of pattern recognition receptors expressed on host cells
Metagenome	The collection of genomes from members of a specific microbiota
Microorganism-associated molecular patterns (MAMPs)	Conserved structural components such as lipopolysaccharide, flagellin and nucleic acids derived from microorganisms that are detected by the host innate immune system
Muramyl dipeptide	A peptidoglycan derivative that is common to both Gram-positive and Gram-negative bacterial cell walls and that triggers an innate immune response
Mutualism	A relationship between two organisms, in which both organisms benefit
Obligate anaerobic bacteria	Bacteria that grow without the need for oxygen
Parasitism	A relationship in which one organism (pathogen) benefits at the expense of another organism
Pathobionts	Normally innocuous microorganisms that can behave like pathogens if their abundance increases and/or their environmental conditions change
Stratum corneum	The outermost layer of the epidermis that forms the protective layer of the skin
Toll-like receptor (TLR)	A family of evolutionarily conserved receptors that recognize microorganism-associated molecular patterns such as flagellin, lipopolysaccharide or nucleic acids. These receptors have an essential role in innate immune responses
Tumour tolerance	A state of immune hyporesponsiveness, in which tumour antigens induce T cell tolerance (a process that allows tumour immune evasion)
Virulence factors	Molecules expressed by pathogenic microorganisms that help them to gain a growth advantage in a specific ecosystem. These molecules are often responsible for disease manifestation in the host

References

1. Koch, R. Tenth International Congress of Medicine 1. August Hirschwald; Berlin: 1891.

2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet*. 2001; 357:539–545. [PubMed: 11229684]
3. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. *Annu Rev Immunol*. 2012; 30:677–706. [PubMed: 2224761]
4. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. *Nature Rev Cancer*. 2010; 10:878–889. [PubMed: 21102637]
5. Virchow, R. Die krankhaften Geschwülste. Virchow, R., editor. Verlag von August von Hirschwald; Berlin: 1863. p. 57–101.
6. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. *Cell*. 2010; 140:883–899. [PubMed: 20303878]
7. Turnbaugh PJ, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature*. 2006; 444:1027–1031. [PubMed: 17183312]
8. Smith MI, et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. *Science*. 2013; 339:548–554. [PubMed: 23363771]
9. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. *EMBO Rep*. 2006; 7:688–693. [PubMed: 16819463]
10. Savage DC. Microbial ecology of the gastrointestinal tract. *Annu Rev Microbiol*. 1977; 31:107–133. [PubMed: 334036]
11. Gill SR, et al. Metagenomic analysis of the human distal gut microbiome. *Science*. 2006; 312:1355–1359. [PubMed: 16741115]
12. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. *Nature*. 2011; 474:327–336. [PubMed: 21677749]
13. Fraher MH, O'Toole PW, Quigley EM. Techniques used to characterize the gut microbiota: a guide for the clinician. *Nature Rev Gastroenterol Hepatol*. 2012; 9:312–322. [PubMed: 22450307]
14. Consortium HMP. Structure, function and diversity of the healthy human microbiome. *Nature*. 2012; 486:207–214. [PubMed: 22699609]
15. Colditz GA, Sellers TA, Trapido E. Epidemiology — identifying the causes and preventability of cancer? *Nature Rev Cancer*. 2006; 6:75–83. [PubMed: 16372016]
16. Peto J. Cancer epidemiology in the last century and the next decade. *Nature*. 2001; 411:390–395. [PubMed: 11357148]
17. Grice EA, Segre JA. The skin microbiome. *Nature Rev Microbiol*. 2011; 9:244–253. [PubMed: 21407241]
18. Eckburg PB, et al. Diversity of the human intestinal microbial flora. *Science*. 2005; 308:1635–1638. [PubMed: 15831718]
19. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. *Hepatology*. 2005; 41:422–433. [PubMed: 15723320]
20. Seki E, et al. TLR4 enhances TGF- β signaling and hepatic fibrosis. *Nature Med*. 2007; 13:1324–1332. [PubMed: 17952090]
21. Dapito DH, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. *Cancer Cell*. 2012; 21:504–516. [PubMed: 22516259]
22. Yoshimoto S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. *Nature*. 2013; 499:97–101. [PubMed: 23803760]
23. Sacksteder MR. Occurrence of spontaneous tumors in the germfree F344 rat. *J Natl Cancer Inst*. 1976; 57:1371–1373. [PubMed: 1069860]
24. Schreiber H, Nettesheim P, Lijinsky W, Richter CB, Walburg HE. Jr Induction of lung cancer in germfree, specific-pathogen-free, and infected rats by *N*-nitrosoheptamethyleneimine: enhancement by respiratory infection. *J Natl Cancer Inst*. 1972; 49:1107–1114. [PubMed: 5084122]
25. Reddy BS, et al. Colon carcinogenesis with azoxymethane and dimethylhydrazine in germ-free rats. *Cancer Res*. 1975; 35:287–290. [PubMed: 162868]
26. Reddy BS, Watanabe K. Effect of intestinal microflora on 2,2'-dimethyl-4-aminobiphenyl-induced carcinogenesis in F344 rats. *J Natl Cancer Inst*. 1978; 61:1269–1271. [PubMed: 280712]

27. Reddy BS, Weisburger JH, Narisawa T, Wynder EL. Colon carcinogenesis in germ-free rats with 1,2-dimethylhydrazine and *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine. *Cancer Res.* 1974; 34:2368–2372. [PubMed: 4843537]
28. Laqueur GL, Matsumoto H, Yamamoto RS. Comparison of the carcinogenicity of methylazoxymethanol- β -D-glucosiduronic acid in conventional and germfree Sprague-Dawley rats. *J Natl Cancer Inst.* 1981; 67:1053–1055. [PubMed: 6946247]
29. Uronis JM, et al. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. *PLoS ONE.* 2009; 4:e6026. [PubMed: 19551144]
30. Lofgren JL, et al. Lack of commensal flora in *Helicobacter pylori*-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. *Gastroenterology.* 2011; 140:210–220. [PubMed: 20950613]
31. Li Y, et al. Gut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in *APC*^{Min/+} mice. *Carcinogenesis.* 2012; 33:1231–1238. [PubMed: 22461519]
32. Vannucci L, et al. Colorectal carcinogenesis in germfree and conventionally reared rats: different intestinal environments affect the systemic immunity. *Int J Oncol.* 2008; 32:609–617. [PubMed: 18292938]
33. Dove WF, et al. Intestinal neoplasia in the *Apc*^{Min} mouse: independence from the microbial and natural killer (*beige* locus) status. *Cancer Res.* 1997; 57:812–814. [PubMed: 9041176]
34. Chen GY, Shaw MH, Redondo G, Nunez G. The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. *Cancer Res.* 2008; 68:10060–10067. [PubMed: 19074871]
35. Yu LX, et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. *Hepatology.* 2010; 52:1322–1333. [PubMed: 20803560]
36. Grivennikov SI, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. *Nature.* 2012; 491:254–258. [PubMed: 23034650]
37. Klimesova K, et al. Altered gut microbiota promotes colitis-associated cancer in IL-1 receptor-associated kinase M-deficient mice. *Inflamm Bowel Dis.* 2013; 19:1266–1277. [PubMed: 23567778]
38. Lee CW, et al. *Helicobacter pylori* eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. *Cancer Res.* 2008; 68:3540–3548. [PubMed: 18441088]
39. Ma JL, et al. Fifteen-year effects of *Helicobacter pylori*, garlic, and vitamin treatments on gastric cancer incidence and mortality. *J Natl Cancer Inst.* 2012; 104:488–492. [PubMed: 22271764]
40. Wong BC, et al. *Helicobacter pylori* eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. *JAMA.* 2004; 291:187–194. [PubMed: 14722144]
41. Coley WB. Treatment of inoperable malignant tumors with the toxins of erysipelas and the *Bacillus prodigiosus*. *Trans Amer Surg Assn.* 1894; 12:183–212.
42. Starnes CO. Coley's toxins in perspective. *Nature.* 1992; 357:11–12. [PubMed: 1574121]
43. Shear MJ, Andervont HB. Chemical treatment of tumors. III separation of hemorrhage-producing fraction of *B coli* filtrate. *Exp Biol Med (Maywood).* 1936; 34:323–324.
44. Pradere JP, Dapito DH, Schwabe RF. The yin and yang of toll-like receptors in cancer. *Oncogene.* 2013. <http://dx.doi.org/10.1038/onc.2013.302>
45. Garaude J, Kent A, van Rooijen N, Blander JM. Simultaneous targeting of Toll- and NOD-like receptors induces effective tumor-specific immune responses. *Sci Transl Med.* 2012; 4:120ra16.
46. Peek RM Jr, Blaser MJ. *Helicobacter pylori* and gastrointestinal tract adenocarcinomas. *Nature Rev Cancer.* 2002; 2:28–37. [PubMed: 11902583]
47. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. *J Clin Invest.* 2007; 117:60–69. [PubMed: 17200707]
48. Islami F, Kamangar F. *Helicobacter pylori* and esophageal cancer risk: a meta-analysis. *Cancer Prev Res (Phila).* 2008; 1:329–338. [PubMed: 19138977]
49. Caygill CP, Hill MJ, Braddick M, Sharp JC. Cancer mortality in chronic typhoid and paratyphoid carriers. *Lancet.* 1994; 343:83–84. [PubMed: 7903779]
50. Welton JC, Marr JS, Friedman SM. Association between hepatobiliary cancer and typhoid carrier state. *Lancet.* 1979; 1:791–794. [PubMed: 86039]

51. Wotherspoon AC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of *Helicobacter pylori*. *Lancet*. 1993; 342:575–577. [PubMed: 8102719]
52. Lecuit M, et al. Immunoproliferative small intestinal disease associated with *Campylobacter jejuni*. *N Engl J Med*. 2004; 350:239–248. [PubMed: 14724303]
53. Senff NJ, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. *Blood*. 2008; 112:1600–1609. [PubMed: 18567836]
54. Ferreri AJ, et al. *Chlamydomphila psittaci* eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. *J Clin Oncol*. 2012; 30:2988–2994. [PubMed: 22802315]
55. Grivennikov SI. Inflammation and colorectal cancer: colitis-associated neoplasia. *Semin Immunopathol*. 2012; 35:229–244. [PubMed: 23161445]
56. Ochi A, et al. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. *J Exp Med*. 2012; 209:1671–1687. [PubMed: 22908323]
57. Michaud DS, Joshipura K, Giovannucci E, Fuchs CS. A prospective study of periodontal disease and pancreatic cancer in US male health professionals. *J Natl Cancer Inst*. 2007; 99:171–175. [PubMed: 17228001]
58. Farrell JJ, et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. *Gut*. 2012; 61:582–588. [PubMed: 21994333]
59. Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. *PLoS ONE*. 2012; 7:e47305. [PubMed: 23071781]
60. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. *N Engl J Med*. 2008; 359:2355–2365. [PubMed: 19038881]
61. Houghton AM. Mechanistic links between COPD and lung cancer. *Nature Rev Cancer*. 2013; 13:233–245. [PubMed: 23467302]
62. Melkamu T, Qian X, Upadhyaya P, O’Sullivan MG, Kassie F. Lipopolysaccharide enhances mouse lung tumorigenesis: a model for inflammation-driven lung cancer. *Vet Pathol*. 2013; 50:895–902. [PubMed: 23381924]
63. Swann JB, et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. *Proc Natl Acad Sci USA*. 2008; 105:652–656. [PubMed: 18178624]
64. Mittal D, et al. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. *EMBO J*. 2010; 29:2242–2252. [PubMed: 20526283]
65. Cataisson C, et al. IL-1R–MyD88 signaling in keratinocyte transformation and carcinogenesis. *J Exp Med*. 2012; 209:1689–1702. [PubMed: 22908325]
66. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host–bacterial mutualism in the human intestine. *Science*. 2005; 307:1915–1920. [PubMed: 15790844]
67. Dethlefsen L, McFall-Ngai M, Relman DA. An ecological and evolutionary perspective on human-microbe mutualism and disease. *Nature*. 2007; 449:811–818. [PubMed: 17943117]
68. Elloe-Fadrosh EA, Rasko DA. The human microbiome: from symbiosis to pathogenesis. *Annu Rev Med*. 2013; 64:145–163. [PubMed: 23327521]
69. Salzman NH, Underwood MA, Bevins CL. Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa. *Semin Immunol*. 2007; 19:70–83. [PubMed: 17485224]
70. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. *Nature Rev Immunol*. 2009; 9:679–691. [PubMed: 19763149]
71. Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. *Cell*. 2010; 140:845–858. [PubMed: 20303875]
72. Pabst O. New concepts in the generation and functions of IgA. *Nature Rev Immunol*. 2012; 12:821–832. [PubMed: 23103985]
73. Ashida H, Ogawa M, Kim M, Mimuro H, Sasakawa C. Bacteria and host interactions in the gut epithelial barrier. *Nature Chem Biol*. 2011; 8:36–45. [PubMed: 22173358]

74. van Nood E, et al. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med*. 2013; 368:407–415. [PubMed: 23323867]
75. Kamada N, et al. Regulated virulence controls the ability of a pathogen to compete with the gut microbiota. *Science*. 2012; 336:1325–1329. [PubMed: 22582016]
76. Cornforth DM, Foster KR. Competition sensing: the social side of bacterial stress responses. *Nature Rev Microbiol*. 2013; 11:285–293. [PubMed: 23456045]
77. Arthur JC, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. *Science*. 2012; 338:120–123. [PubMed: 22903521]
78. Couturier-Maillard A, et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. *J Clin Invest*. 2013; 123:700–711. [PubMed: 23281400]
79. Hu B, et al. Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. *Proc Natl Acad Sci USA*. 2013; 110:9862–9867. [PubMed: 23696660]
80. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. *Nature*. 2011; 474:307–317. [PubMed: 21677747]
81. Houlston RS, et al. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. *Nature Genet*. 2010; 42:973–977. [PubMed: 20972440]
82. Peters U, et al. Identification of genetic susceptibility loci for colorectal tumors in a genome-wide metaanalysis. *Gastroenterology*. 2013; 144:799–807. [PubMed: 23266556]
83. Velcich A, et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. *Science*. 2002; 295:1726–1729. [PubMed: 11872843]
84. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. *N Engl J Med*. 2011; 365:1315–1327. [PubMed: 21991953]
85. Costello EK, et al. Bacterial community variation in human body habitats across space and time. *Science*. 2009; 326:1694–1697. [PubMed: 19892944]
86. Caporaso JG, et al. Moving pictures of the human microbiome. *Genome Biol*. 2011; 12:R50. [PubMed: 21624126]
87. Holmes E, Li JV, Marchesi JR, Nicholson JK. Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. *Cell Metab*. 2012; 16:559–564. [PubMed: 23140640]
88. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. *Nature*. 2006; 444:1022–1023. [PubMed: 17183309]
89. Ward JM, et al. Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel *Helicobacter* species. *J Natl Cancer Inst*. 1994; 86:1222–1227. [PubMed: 8040890]
90. Erdman SE, et al. Nitric oxide and TNF- α trigger colonic inflammation and carcinogenesis in *Helicobacter hepaticus*-infected, Rag2-deficient mice. *Proc Natl Acad Sci USA*. 2009; 106:1027–1032. [PubMed: 19164562]
91. Kim SC, et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. *Gastroenterology*. 2005; 128:891–906. [PubMed: 15825073]
92. Wu S, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. *Nature Med*. 2009; 15:1016–1022. [PubMed: 19701202]
93. Boulard O, Kirchberger S, Royston DJ, Maloy KJ, Powrie FM. Identification of a genetic locus controlling bacteria-driven colitis and associated cancer through effects on innate inflammation. *J Exp Med*. 2012; 209:1309–1324. [PubMed: 22734048]
94. Rao VP, et al. Proinflammatory CD4⁺ CD45RB^{hi} lymphocytes promote mammary and intestinal carcinogenesis in *Apc*^{Min/+} mice. *Cancer Res*. 2006; 66:57–61. [PubMed: 16397216]
95. Garrett WS, et al. Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. *Cancer Cell*. 2009; 16:208–219. [PubMed: 19732721]

96. Zhang HL, et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. *J Hepatol.* 2012; 57:803–812. [PubMed: 22727732]
97. Ley RE, et al. Obesity alters gut microbial ecology. *Proc Natl Acad Sci USA.* 2005; 102:11070–11075. [PubMed: 16033867]
98. Cotillard A, et al. Dietary intervention impact on gut microbial gene richness. *Nature.* 2013; 500:585–588. [PubMed: 23985875]
99. Le Chatelier E, et al. Richness of human gut microbiome correlates with metabolic markers. *Nature.* 2013; 500:541–546. [PubMed: 23985870]
100. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. *Nature Rev Cancer.* 2004; 4:579–591. [PubMed: 15286738]
101. Devkota S, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in *Il10^{-/-}* mice. *Nature.* 2012; 487:104–108. [PubMed: 22722865]
102. Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. *PLoS ONE.* 2012; 7:e39743. [PubMed: 22761885]
103. Sanapareddy N, et al. Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans. *ISME J.* 2012; 6:1858–1868. [PubMed: 22622349]
104. Sobhani I, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. *PLoS ONE.* 2011; 6:e16393. [PubMed: 21297998]
105. Wang T, et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. *ISME J.* 2011; 6:320–329. [PubMed: 21850056]
106. Kostic AD, et al. Genomic analysis identifies association of *Fusobacterium* with colorectal carcinoma. *Genome Res.* 2012; 22:292–298. [PubMed: 22009990]
107. Kostic AD, et al. *Fusobacterium nucleatum* potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. *Cell Host Microbe.* 2013; 14:207–215. [PubMed: 23954159]
108. McCoy AN, et al. *Fusobacterium* is associated with colorectal adenomas. *PLoS ONE.* 2013; 8:e53653. [PubMed: 23335968]
109. Rubinstein MR, et al. *Fusobacterium nucleatum* promotes colorectal carcinogenesis by modulating E-cadherin/ β -catenin signaling via its FadA adhesin. *Cell Host Microbe.* 2013; 14:195–206. [PubMed: 23954158]
110. Allen-Vergee E, Strauss J, Chadee K. *Fusobacterium nucleatum*: an emerging gut pathogen? *Gut Microbes.* 2011; 2:294–298. [PubMed: 22067936]
111. Stecher B, et al. Gut inflammation can boost horizontal gene transfer between pathogenic and commensal Enterobacteriaceae. *Proc Natl Acad Sci USA.* 2012; 109:1269–1274. [PubMed: 22232693]
112. Elinav E, Strowig T, Henao-Mejia J, Flavell RA. Regulation of the antimicrobial response by NLR proteins. *Immunity.* 2011; 34:665–679. [PubMed: 21616436]
113. Winter SE, et al. Host-derived nitrate boosts growth of *E. coli* in the inflamed gut. *Science.* 2013; 339:708–711. [PubMed: 23393266]
114. Lupp C, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. *Cell Host Microbe.* 2007; 2:204. [PubMed: 18030708]
115. Morgan XC, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. *Genome Biol.* 2012; 13:R79. [PubMed: 23013615]
116. Vijay-Kumar M, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. *Science.* 2012; 328:228–231. [PubMed: 20203013]
117. Patwa LG, et al. Chronic intestinal inflammation induces stress-response genes in commensal *Escherichia coli*. *Gastroenterology.* 2011; 141:1842–1851. [PubMed: 21726510]
118. Hajishengallis G, Darveau RP, Curtis MA. The keystone-pathogen hypothesis. *Nature Rev Microbiol.* 2012; 10:717–725. [PubMed: 22941505]
119. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* 2011; 144:646–674. [PubMed: 21376230]

120. Moresco EM, LaVine D, Beutler B. Toll-like receptors. *Curr Biol*. 2011; 21:R488–R493. [PubMed: 21741580]
121. Fukata M, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. *Gastroenterology*. 2007; 133:1869–1881. [PubMed: 18054559]
122. Fukata M, et al. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. *Inflamm Bowel Dis*. 2011; 17:1464–1473. [PubMed: 21674704]
123. Tye H, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. *Cancer Cell*. 2012; 22:466–478. [PubMed: 23079657]
124. Ngo VN, et al. Oncogenically active MYD88 mutations in human lymphoma. *Nature*. 2011; 470:115–119. [PubMed: 21179087]
125. Brandl K, et al. MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands. *Proc Natl Acad Sci USA*. 2010; 107:19967–19972. [PubMed: 21041656]
126. Neufert C, et al. Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. *J Clin Invest*. 2013; 123:1428–1443. [PubMed: 23549083]
127. Naugler WE, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. *Science*. 2007; 317:121–124. [PubMed: 17615358]
128. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. *Science*. 2007; 317:124–127. [PubMed: 17615359]
129. Lee SH, et al. ERK activation drives intestinal tumorigenesis in *Apc^{min/+}* mice. *Nature Med*. 2010; 16:665–670. [PubMed: 20473309]
130. Kennedy, CL., et al. Differential role of MyD88 and Mal/TIRAP in TLR2-mediated gastric tumorigenesis. *Oncogene*. 2013. <http://dx.doi.org/10.1038/onc.2013.205>
131. Salcedo R, et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. *J Exp Med*. 2010; 207:1625–1636. [PubMed: 20624890]
132. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. *Nature Rev Immunol*. 2008; 8:458–466. [PubMed: 18500230]
133. Kobayashi KS, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. *Science*. 2005; 307:731–734. [PubMed: 15692051]
134. Petnicki-Ocwieja T, et al. Nod2 is required for the regulation of commensal microbiota in the intestine. *Proc Natl Acad Sci USA*. 2009; 106:15813–15818. [PubMed: 19805227]
135. Rehman A, et al. Nod2 is essential for temporal development of intestinal microbial communities. *Gut*. 2011; 60:1354–1362. [PubMed: 21421666]
136. McGovern DP, et al. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. *Hum Mol Genet*. 2005; 14:1245–1250. [PubMed: 15790594]
137. Allen IC, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. *J Exp Med*. 2010; 207:1045–1056. [PubMed: 20385749]
138. Allen IC, et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF- κ B signaling. *Immunity*. 2012; 36:742–754. [PubMed: 22503542]
139. Hu B, et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. *Proc Natl Acad Sci USA*. 2010; 107:21635–21640. [PubMed: 21118981]
140. Travaglione S, Fabbri A, Fiorentini C. The Rho-activating CNF1 toxin from pathogenic *E. coli*: a risk factor for human cancer development? *Infect Agent Cancer*. 2008; 3:4. [PubMed: 18336718]
141. Nesic D, Hsu Y, Stebbins CE. Assembly and function of a bacterial genotoxin. *Nature*. 2004; 429:429–433. [PubMed: 15164065]
142. Cuevas-Ramos G, et al. *Escherichia coli* induces DNA damage *in vivo* and triggers genomic instability in mammalian cells. *Proc Natl Acad Sci USA*. 2010; 107:11537–11542. [PubMed: 20534522]
143. Smith JL, Bayles DO. The contribution of cytolethal distending toxin to bacterial pathogenesis. *Crit Rev Microbiol*. 2006; 32:227–248. [PubMed: 17123907]

144. Elwell CA, Dreyfus LA. DNase I homologous residues in CdtB are critical for cytolethal distending toxin-mediated cell cycle arrest. *Mol Microbiol.* 2000; 37:952–963. [PubMed: 10972814]
145. Fox JG, et al. Gastroenteritis in NF- κ B-deficient mice is produced with wild-type *Campylobacter jejuni* but not with *C. jejuni* lacking cytolethal distending toxin despite persistent colonization with both strains. *Infect Immun.* 2004; 72:1116–1125. [PubMed: 14742559]
146. Shen Z, et al. Cytolethal distending toxin promotes *Helicobacter cinaedi*-associated typhlocolitis in interleukin-10-deficient mice. *Infect Immun.* 2009; 77:2508–2516. [PubMed: 19307212]
147. Nougayrede JP, et al. *Escherichia coli* induces DNA double-strand breaks in eukaryotic cells. *Science.* 2006; 313:848–851. [PubMed: 16902142]
148. Buc E, et al. High prevalence of mucosa-associated *E. coli* producing cyclomodulin and genotoxin in colon cancer. *PLoS ONE.* 2013; 8:e56964. [PubMed: 23457644]
149. Garrett WS, et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. *Cell Host Microbe.* 2010; 8:292–300. [PubMed: 20833380]
150. Putze J, et al. Genetic structure and distribution of the colibactin genomic island among members of the family Enterobacteriaceae. *Infect Immun.* 2009; 77:4696–4703. [PubMed: 19720753]
151. Carbonero F, Benefiel AC, Alizadeh-Ghamsari AH, Gaskins HR. Microbial pathways in colonic sulfur metabolism and links with health and disease. *Front Physiol.* 2012; 3:448. [PubMed: 23226130]
152. Huycke MM, Gaskins HR. Commensal bacteria, redox stress, and colorectal cancer: mechanisms and models. *Exp Biol Med (Maywood).* 2004; 229:586–597. [PubMed: 15229352]
153. Wang X, Huycke MM. Extracellular superoxide production by *Enterococcus faecalis* promotes chromosomal instability in mammalian cells. *Gastroenterology.* 2007; 132:551–561. [PubMed: 17258726]
154. Wang X, et al. 4-hydroxy-2-nonenal mediates genotoxicity and bystander effects caused by *Enterococcus faecalis*-infected macrophages. *Gastroenterology.* 2012; 142:543–551. [PubMed: 22108198]
155. Balish E, Warner T. *Enterococcus faecalis* induces inflammatory bowel disease in interleukin-10 knockout mice. *Am J Pathol.* 2002; 160:2253–2257. [PubMed: 12057927]
156. Castellarin M, et al. *Fusobacterium nucleatum* infection is prevalent in human colorectal carcinoma. *Genome Res.* 2012; 22:299–306. [PubMed: 22009989]
157. Attene-Ramos MS, Wagner ED, Plewa MJ, Gaskins HR. Evidence that hydrogen sulfide is a genotoxic agent. *Mol Cancer Res.* 2006; 4:9–14. [PubMed: 16446402]
158. Ohnishi N, et al. Transgenic expression of *Helicobacter pylori* CagA induces gastrointestinal and hematopoietic neoplasms in mouse. *Proc Natl Acad Sci USA.* 2008; 105:1003–1008. [PubMed: 18192401]
159. Han YW, et al. Identification and characterization of a novel adhesin unique to oral fusobacteria. *J Bacteriol.* 2005; 187:5330–5340. [PubMed: 16030227]
160. Philipp B. Bacterial degradation of bile salts. *Appl Microbiol Biotechnol.* 2011; 89:903–915. [PubMed: 21088832]
161. Bernstein C, et al. Carcinogenicity of deoxycholate, a secondary bile acid. *Arch Toxicol.* 2011; 85:863–871. [PubMed: 21267546]
162. Quante M, et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. *Cancer Cell.* 2012; 21:36–51. [PubMed: 22264787]
163. Nyangale EP, Mottram DS, Gibson GR. Gut microbial activity, implications for health and disease: the potential role of metabolite analysis. *J Proteome Res.* 2012; 11:5573–5585. [PubMed: 23116228]
164. Windey K, De Preter V, Verbeke K. Relevance of protein fermentation to gut health. *Mol Nutr Food Res.* 2012; 56:184–196. [PubMed: 22121108]
165. Hawksworth GM, Hill MJ. Bacteria and the N-nitrosation of secondary amines. *Br J Cancer.* 1971; 25:520–526. [PubMed: 4947346]
166. Alam BS, Saporoschitz IB, Epstein SS. Synthesis of nitrosopiperidine from nitrate and piperidine in the gastro-intestinal tract of the rat. *Nature.* 1971; 232:199–200. [PubMed: 4933776]

167. Russell WR, et al. High-protein, reduced carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health. *Am J Clin Nutr.* 2011; 93:1062–1072. [PubMed: 21389180]
168. Bindels LB, et al. Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. *Br J Cancer.* 2012; 107:1337–1344. [PubMed: 22976799]
169. Donohoe DR, et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. *Cell Metab.* 2011; 13:517–526. [PubMed: 21531334]
170. Hu S, et al. The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer. *PLoS ONE.* 2011; 6:e16221. [PubMed: 21283757]
171. Maslowski KM, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. *Nature.* 2009; 461:1282–1286. [PubMed: 19865172]
172. Eberhardt MV, Lee CY, Liu RH. Antioxidant activity of fresh apples. *Nature.* 2000; 405:903–904. [PubMed: 10879522]
173. DeWeerd S. Food: The omnivore's labyrinth. *Nature.* 2011; 471:S22–S24. [PubMed: 21430718]
174. Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. *Nature Rev Cancer.* 2009; 9:429–439. [PubMed: 19472429]
175. van Duynhoven J, et al. Metabolic fate of polyphenols in the human superorganism. *Proc Natl Acad Sci USA.* 2011; 108(Suppl 1):4531–4538. [PubMed: 20615997]
176. Fardet A, et al. Metabolomics provide new insight on the metabolism of dietary phytochemicals in rats. *J Nutr.* 2008; 138:1282–1287. [PubMed: 18567748]
177. Dutton RJ, Turnbaugh PJ. Taking a metagenomic view of human nutrition. *Curr Opin Clin Nutr Metab Care.* 2012; 15:448–454. [PubMed: 22878238]
178. Chang MC, Keasling JD. Production of isoprenoid pharmaceuticals by engineered microbes. *Nature Chem Biol.* 2006; 2:674–681. [PubMed: 17108985]
179. Mabrok HB, et al. Lignan transformation by gut bacteria lowers tumor burden in a gnotobiotic rat model of breast cancer. *Carcinogenesis.* 2012; 33:203–208. [PubMed: 22080573]
180. Adlercreutz H. Phyto-oestrogens and cancer. *Lancet Oncol.* 2002; 3:364–373. [PubMed: 12107024]
181. Haider HJ, Turnbaugh PJ. Is it time for a metagenomic basis of therapeutics? *Science.* 2012; 336:1253–1255. [PubMed: 22674325]
182. Wallace BD, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. *Science.* 2010; 330:831–835. [PubMed: 21051639]
183. Kassie F, et al. Intestinal microflora plays a crucial role in the genotoxicity of the cooked food mutagen 2-amino-3-methylimidazo [4,5-f]quinoline. *Carcinogenesis.* 2001; 22:1721–1725. [PubMed: 11577015]
184. Hirayama K, et al. Effects of human intestinal flora on mutagenicity of and DNA adduct formation from food and environmental mutagens. *Carcinogenesis.* 2000; 21:2105–2111. [PubMed: 11062175]
185. Vanhaecke L, et al. Intestinal bacteria metabolize the dietary carcinogen 2-amino-1-methyl- 6-phenylimidazo[4,5-b]pyridine following consumption of a single cooked chicken meal in humans. *Food Chem Toxicol.* 2008; 46:140–148. [PubMed: 17766021]
186. Sharp JO, Wood TK, Alvarez-Cohen L. Aerobic biodegradation of *N*-nitrosodimethylamine (NDMA) by axenic bacterial strains. *Biotechnol Bioeng.* 2005; 89:608–618. [PubMed: 15672376]
187. Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. *Nature Rev Cancer.* 2007; 7:599–612. [PubMed: 17646865]
188. Seitz HK, et al. Possible role of acetaldehyde in ethanol-related rectal cocarcinogenesis in the rat. *Gastroenterology.* 1990; 98:406–413. [PubMed: 2295396]
189. Plottel CS, Blaser MJ. Microbiome and malignancy. *Cell Host Microbe.* 2011; 10:324–335. [PubMed: 22018233]
190. Markle JG, et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. *Science.* 2013; 339:1084–1088. [PubMed: 23328391]

191. Chung H, et al. Gut immune maturation depends on colonization with a host-specific microbiota. *Cell*. 2012; 149:1578–1593. [PubMed: 22726443]
192. Singh S, Eldin C, Kowalczywska M, Raoult D. Axenic culture of fastidious and intracellular bacteria. *Trends Microbiol*. 2013; 21:92–99. [PubMed: 23182864]
193. Bull AT. The renaissance of continuous culture in the post-genomics age. *J Ind Microbiol Biotechnol*. 2010; 37:993–1021. [PubMed: 20835748]
194. Arthur JC, Jobin C. The complex interplay between inflammation, the microbiota and colorectal cancer. *Gut Microbes*. 2013; 4:253–258. [PubMed: 23549517]
195. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. *Science*. 2012; 336:1268–1273. [PubMed: 22674334]
196. Ubeda C, et al. Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice. *J Exp Med*. 2012; 209:1445–1456. [PubMed: 22826298]
197. Shanahan, MT., et al. Mouse Paneth cell antimicrobial function is independent of Nod2. *Gut*. 2013. <http://dx.doi.org/10.1136/gutjnl-2012-304190>
198. Robertson SJ, et al. Nod1 and Nod2 signaling does not alter the composition of intestinal bacterial communities at homeostasis. *Gut Microbes*. 2013; 4:222–231. [PubMed: 23549220]
199. McCafferty, J., et al. Stochastic changes over time and not founder effects drive cage effects in microbial community assembly in a mouse model. *ISME J*. 2013. <http://dx.doi.org/10.1038/ismej.2013.106>
200. Khazaie K, et al. Abating colon cancer polyposis by *Lactobacillus acidophilus* deficient in lipoteichoic acid. *Proc Natl Acad Sci USA*. 2012; 109:10462–10467. [PubMed: 22689992]




Figure 1. Mechanisms controlling host–microbiota interactions and associated failures implicated in cancer development

A state of homeostasis and symbiotic relationships is maintained by the separation of microbial entities from the host through a multi-level barrier, by a eubiotic microbiome that actively suppresses pathobionts and that maintains a symbiotic relationship with the host, and by a state of low inflammation in the host. Perturbation of this balance leads to chain reactions that ultimately result in a cancer-promoting state with a failing barrier, inflammation and dysbiosis. This state includes qualitative and sometimes quantitative changes in the microbiota; failure of the barrier either physically (for example, at the level of tight junctions or at the mucous layer), or at the level of antibacterial defence systems — either those of epithelial cells or those of cells from the gut-associated lymphoid tissue (GALT); and increased inflammatory responses, which are often mediated by pattern recognition receptors (PRRs) and downstream cytokines that promote epithelial cell proliferation and survival. DCA, deoxycholic acid; EREG, epiregulin; IgA, immunoglobulin A; IL-6, interleukin-6; MAMP, microorganism-associated molecular pattern; NF-κB, nuclear factor-κB; TH17, T helper 17; TNF, tumour necrosis factor.




Figure 2. Mechanisms by which the bacterial microbiome modulates carcinogenesis

The bacterial microbiome promotes carcinogenesis through several mechanisms. **a** | Changes in the microbiome and host defences may favour increased bacterial translocation, leading to increased inflammation, which is mediated by microorganism-associated molecular patterns (MAMPs) that activate Toll-like receptors (TLRs) in several cell types, including macrophages, myofibroblasts, epithelial cells and tumour cells. These effects may occur locally or through long-distance effects in other organs. **b** | Genotoxic effects are mediated by bacterial genotoxins — such as colibactin and cytolethal distending toxin (CDT) — that, after being delivered to the nucleus of host cells, actively induce DNA damage in organs that are in direct contact with the microbiome, such as the gastrointestinal tract. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) released from inflammatory cells such as macrophages, as well as hydrogen sulphide (H₂S) from the bacterial microbiota, may also be genotoxic. **c** | Metabolic actions of the microbiome may result in the activation of genotoxins such as acetaldehyde, dietary nitrosamine and other carcinogens, in the metabolism of hormones such as oestrogen and testosterone, in the metabolism of bile acids and in alterations of energy harvest. The microbiota also mediates tumour suppressive effects (shown in green) through inactivation of carcinogens, through the generation of short-chain fatty acids such as butyrate and through the biological activation of cancer-preventing phytochemicals. Many of these tumorigenic and tumour-suppressive mediators exert both local and longdistance effects. AREG, amphiregulin; DCA, deoxycholic acid; EREG, epiregulin; IL, interleukin; NF-κB, nuclear factor-κB; NLR,

NOD-like receptor; STAT3, signal transducer and activator of transcription 3; T_H17, T helper 17; TNF, tumour necrosis factor.




Figure 3. Targeting the bacterial microbiota for therapeutic modulation of carcinogenesis

On the basis of the known contribution of the bacterial microbiota in experimental carcinogenesis, the approaches shown are conceivable for the prevention of human carcinogenesis.

Table 1

Evidence for tumour-promoting effects of the bacterial microbiota

Cancer type	Disease or model	Findings	Refs
Murine studies			
Colorectal cancer	Germ-free rats and spontaneous carcinogenesis	Fewer tumours in germ-free rats	23
	Germ-free rats and DMH-induced	Fewer tumours in germ-free rats	25
	Germ-free rats and AOM-induced	More tumours in germ-free rats	28
	Germ-free rats and MAM-GlcUA	Fewer tumours in germ-free rats	28
	Germ-free rats and AOM-induced	Fewer tumours in germ-free rats	32
	AOM in <i>Il10</i> ^{-/-} gnotobiotic mice	Fewer tumours in germ-free mice	29
	Germ-free <i>Apc</i> ^{Min/+} mice	Fewer tumours in germ-free mice	31
	<i>Apc</i> ^{Min/+} <i>Cdx2</i> -Cre mice treated with antibiotic cocktail	Fewer tumours in antibiotic-treated mice	36
	<i>Nod1</i> ^{-/-} mice treated with antibiotic cocktail	Fewer tumours in antibiotic-treated mice	34
	AOM plus DSS -treated mice treated with antibiotic cocktail	Fewer tumours in antibiotic-treated mice	37
	Wild-type microbiota transplanted into <i>Nod2</i> ^{-/-} mice	Fewer tumours after transplant	78
Gastric cancer	<i>Helicobacter pylori</i> -infected gnotobiotic INS-GAS mice	Fewer tumours in germ-free mice	30
	<i>H. pylori</i> -infected INS-GAS mice, treated with antibiotic	Fewer tumours in antibiotic-treated mice	38
Liver cancer	DEN plus CCl ₄ -treated germ-free mice	Fewer tumours in germ-free mice	21
	DEN plus CCl ₄ -treated mice, receiving antibiotic cocktail	Fewer tumours in antibiotic-treated mice	21
	DEN plus CCl ₄ -treated mice, receiving rifaximin	Fewer tumours in rifaximin-treated mice	21
	DEN-treated rats, receiving neomycin	Fewer tumours in neomycin-treated rats	35
	DMBA and high-fat-diet-treated mice, receiving antibiotic cocktail	Fewer tumours in antibiotic-treated mice	22
	DMBA and high-fat-diet-treated mice, receiving vancomycin	Fewer tumours in vancomycin-treated mice	22
Lung cancer	NHMI-treated germ-free rats	• Fewer tumours in male germ-free rats	24
		• No change in female germ-free rats	
Breast cancer	DMAB-treated germ-free rats	Reduced tumours in germ-free rats	26
Human studies			
Gastric cancer	<i>H. pylori</i> eradication by antibiotics	Reduced cancer in antibiotic-treated patients	39,40
Gastric MALT lymphoma	<i>H. pylori</i> eradication by antibiotics	Regression after eradication	51
Skin MALT lymphoma	<i>Borrelia burgdorferi</i> eradication by antibiotics	Regression after eradication	53
IPSID	<i>Campylobacter jejuni</i> eradication by antibiotics	Regression after eradication	52
Ocular adnexal lymphoma	<i>Chlamydia psittaci</i> eradication by doxycycline	Regression after eradication	54

AOM, azoxymethane; *Apc*, adenomatous polyposis coli; CCl₄, carbon tetrachloride; *Cdx2*, caudal type homeobox 2; DEN, diethylnitrosamine; DMAB, 3,2'-dimethyl- 4-aminobiphenyl hydrochloride; DMH, dimethylhydrazine; DSS, dextran sodium sulphate; *Il10*, interleukin-10; IPSID,

immunoproliferative small intestinal disease; MALT, mucosa-associated lymphoid tissue; MAM-GlcUA, methylazoxymethanol- β -D-glucosiduronic acid; NHMI, *N*-nitrosoheptamethyleneimine; *Nod*, nucleotide-binding oligomerization domain-containing.

Table 2

Mechanisms by which the bacterial microbiota contribute to carcinogenesis

Cancer	Mechanism	Evidence	Refs
Cancers promoted or inhibited by specific bacterial pathogens			
Gastric cancer	Chronic infection with <i>Helicobacter pylori</i>	- Epidemiology - Reduction by <i>H. pylori</i> eradication	39,40, 46,47
- Gastric MALT lymphoma - IPSID - Skin MALT lymphoma - Ocular adnexal lymphoma	Uncontrolled adaptive immune responses in patients with chronic infection with <i>H. pylori</i> , <i>Campylobacter jejuni</i> , <i>Borellia burgdorferi</i> or <i>Chlamydia psittaci</i>	- Epidemiology - Antibiotic treatment	52–54
Gallbladder cancer	Chronic infection with <i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Typhi	Epidemiology	49,50
Oesophageal cancer	Reduced risk in patients with <i>H. pylori</i> infection	Epidemiology	46,48
Cancers promoted by specific pathogens (in mice only)			
Breast cancer	Increased inflammation, mediated by T regulatory cells	Cancer promoted in <i>Helicobacter hepaticus</i> -infected <i>Apc</i> ^{Min/+} mice	94
Liver cancer	Chronic hepatitis	Cancer promoted in <i>H. hepaticus</i> -infected mice	89
Colorectal cancer	TNF-mediated and NO-mediated	Cancer promoted in <i>H. hepaticus</i> -infected <i>Rag2</i> ^{-/-} mice	90
Cancers suspected to be promoted by commensal bacteria or dysbiotic microbiomes			
Colorectal cancer	- Dysbiosis - Barrier failure - Chronic inflammation - Bacterial genotoxicity	Cancer reduction by antibiotics and in germ-free mice; transmission of dysbiotic microbiota triggers cancer development	25,27, 32–34,36
Liver cancer	- Increased hepatic exposure to TLR-activating MAMPs - Increased exposure to the secondary bile acid DCA	- Cancer reduction by treatment with antibiotics and in germ-free mice - Cancer increased by treatment with LPS and DCA	21,22,35
Lung cancer	Increased bacterial infection in COPD?	- Decreased cancer in germ-free animals - Promotion of cancer by LPS and infections	24,59–62
Pancreatic cancer	LPS–TLR4-mediated increase of pancreatic cancer	LPS treatment increases cancer development	56–58

Apc, adenomatous polyposis coli; COPD, chronic obstructive pulmonary disease; DCA, deoxycholic acid; IPSID, immunoproliferative small intestinal disease; LPS, lipopolysaccharide; MALT, mucosa-associated lymphoid tissue; MAMPs, microorganism-associated molecular patterns; NO, nitric oxide; *Rag2*, recombination activating gene 2; TLR, Toll-like receptor; TNF, tumour necrosis factor.